Exagen Inc. Appoints Chas McKhann to Board of Directors
MWN-AI** Summary
Exagen Inc. (Nasdaq: XGN), a prominent provider of innovative autoimmune testing solutions, has announced the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. With over 25 years of experience in the life sciences sector, Mr. McKhann brings a wealth of knowledge and leadership skills, particularly in turnaround and transformational growth strategies within medical technology companies. His most recent roles include Board member, President, and CEO of Silk Road Medical and leadership positions at Apollo Endosurgery, both of which were acquired by Boston Scientific, yielding significant shareholder returns.
John Aballi, President and CEO of Exagen, expressed enthusiasm for Mr. McKhann's appointment, stating that his extensive experience will be vital as Exagen continues to prioritize innovation and improved patient care. Mr. McKhann himself highlighted his honor in joining Exagen, a company committed to transforming autoimmune diagnostics, and expressed eagerness to contribute to the company's strategic growth and long-term value.
Exagen Inc. is dedicated to enhancing the care of patients with chronic autoimmune conditions. Based in California, Exagen's mission focuses on providing clarity in diagnosing autoimmune diseases through its progressive testing solutions, notably the AVISE® CTD product, which aids clinicians in diagnosing complex conditions like lupus and rheumatoid arthritis with greater accuracy. The company’s laboratory specializes in rheumatic disease testing, emphasizing timely and precise results.
Exagen is committed to research, innovation, and patient-centered care, and continues to focus on addressing the challenges of autoimmune disease management. The company warns that its forward-looking statements regarding growth and business strategies are subject to uncertainties, including reimbursement and regulatory factors. For further information on Exagen's offerings and updates, visit Exagen.com or follow @ExagenInc on social media platforms.
MWN-AI** Analysis
Exagen Inc. (Nasdaq: XGN) has made a significant move by appointing Chas McKhann to its Board of Directors, a decision that could have ramifications for the company's future growth and market standing. McKhann's wealth of experience in the life sciences sector—particularly in leading successful transformations and driving shareholder value—positions Exagen well, especially as it continues to expand its footprint in the autoimmune diagnostics space.
Exagen's flagship product, the AVISE® CTD test, is integral to its mission of improving the diagnosis of complex autoimmune conditions. McKhann's track record at organizations like Silk Road Medical and Apollo Endosurgery provides a clear signal of his capability to enhance Exagen’s strategic initiatives and operational efficiencies. His familiarity with navigating the challenges that come with innovation in the medical technology sector may help Exagen streamline processes and optimize its product portfolio.
As the company gears up for growth, investors should monitor a few critical factors. First, successful execution of business strategies, particularly in maintaining and expanding market acceptance among rheumatologists and payors, will be pivotal. Furthermore, navigating the complexities of reimbursement landscapes will be essential; any delays in obtaining coverage could impact short-term revenues and long-term sustainability.
Investors should also remain cognizant of regulatory challenges and potential delays in clinical trials that could affect the product pipeline. While the appointment of McKhann is a positive indicator, actual results may vary, and investors should consider the inherent risks involved.
In summary, with Chas McKhann on board, Exagen appears poised for significant advancements in its operational strategy. However, potential investors should weigh these positive developments against the landscape of uncertainties that accompany the life sciences industry. A cautious yet optimistic approach is prudent.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025.
Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholder returns. Previously, Mr. McKhann served as Chief Commercial Officer at Torax Medical and Intersect ENT. Mr. McKhann holds a B.A. in Political Science and an M.B.A. from Stanford University.
“I couldn’t be more excited to welcome Chas to the Board of Directors at Exagen. His exceptional leadership across multiple innovative life science companies and deep commercial expertise will be invaluable as we continue to drive growth and advance patient care,” said John Aballi, President and CEO of Exagen.
“I’m honored to join the Board of Directors at Exagen, a company transforming autoimmune diagnostics through innovation and dedication to patient care. I look forward to working alongside the leadership team and fellow board members to help drive strategic growth and create long-term value for patients, providers, and shareholders,” said McKhann.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow @ExagenInc on X .
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies and ambitions; potential future financial and business performance; the potential utility and effectiveness of Exagen’s services and testing solutions; the expected benefits of Mr. McKhann’s position with Exagen; potential shareholder value and growth and 2025 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525
FAQ**
How will the appointment of Chas McKhann to the Board of Directors impact Exagen Inc. (XGN) in terms of strategic growth and shareholder value?
What specific innovations does Exagen Inc. (XGN) plan to pursue in its autoimmune diagnostics to enhance patient care and clinical outcomes?
Considering Mr. McKhann's experience, what turnaround strategies might he suggest to improve Exagen Inc. (XGN) market acceptance among healthcare providers?
What measures is Exagen Inc. (XGN) taking to address the risks related to reimbursement delays and regulatory interactions as mentioned in the recent press release?
**MWN-AI FAQ is based on asking OpenAI questions about Exagen Inc. (NASDAQ: XGN).
NASDAQ: XGN
XGN Trading
3.08% G/L:
$3.4015 Last:
603,728 Volume:
$3.40 Open:
